JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by CHEN, K. K.
Right arrow Articles by CHEN, A. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by CHEN, K. K.
Right arrow Articles by CHEN, A. L.
Journal of Pharmacology And Experimental Therapeutics, Vol. 49, Issue 4, 561-579, 1933
Copyright © 1933 by American Society for Pharmacology and Experimental Therapeutics

SIMILARITY AND DIS-SIMILARITY OF BUFAGINS, BUFOTOXINS, AND DIGITALOID GLUCOSIDES

K. K. CHEN 1 and A. LING CHEN 1

1 From the Lilly Research Laboratories, Eli Lilly and Company, Indianapolis

A strict comparison of 26 digitalis-like principles, composed of 10 bufagins, 12 bufotoxins, and 4 members of the digitaloid glucosides, has been made from the physical, chemical, and pharmacological points of view. Several features of similarity and dissimilarity have been presented and discussed.

It appears that bufagins and bufotoxins are generically similar, but specifically different. These two classes of compounds are more closely related to scillaren A than to G-strophanthin (ouabain), digitoxin, and thevetin.

Incidently the merits and shortcomings of several methods of digitalis standardization, as revealed by our own experience, have been enumerated.

Submitted on April 3, 1933






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1933 by the American Society for Pharmacology and Experimental Therapeutics.